Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncodesign and OSEO Announce Funding of EUR 13.4 Million

Published: Tuesday, March 12, 2013
Last Updated: Tuesday, March 12, 2013
Bookmark and Share
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.

In the presence of French president, Francois Hollande, Francois Drouin, OSEO's CEO and vice-president of the BPI (Banque Publique d'Investissement), announced to Philippe Genne, Oncodesign's CEO and leader of the IMODI (Innovative MODels Initiative), that this project will receive EUR 13.4 million in funding under the French Government's Investing for the Future program.

The IMODI research project is designed to make the selection of new effective treatments to combat eight cancer pathologies easier.

The aim of this national initiative is to pool the resources allocated to the development, profiling and evaluation of more than 200 predictive experimental cancer models and a wide range of derivative biological products and tests for molecular selection.

The project also plans to create a centralized biobank with more than 40,000 biological samples and powerful data analysis tools designed to identify tumor and immunological biomarkers, as well as those coming from the microbiome.

Under the management and coordination of Oncodesign, the seven-year project brings together six industrial groups (Sanofi, Servier, Ipsen, Pierre Fabre, Transgene and Biofortis), four SMEs (Oncomedics, Ariana Pharma, CTI BIOTECH and Oncodesign) and seven French institutions (Inserm [the French National Institute of Health and Medical Research], CNRS, [the French National Center for Scientific Research], the Georges Francois Leclerc Center in Dijon, the Leon Berard Center in Lyon for cancer research and treatment, Synergie Lyon Cancer, the University of Strasbourg and Toulouse University Hospital).

Each organization belongs to one of five competitiveness clusters with authority to certify projects: Medicen, for the Paris Region, Alsace Biovalley, Lyonbiopole, Atlanpole Biotherapies in Nantes and Cancer-Bio-Sante in Toulouse.

IMODI won the investment for the 'Focal-Point Research and Development Projects for Competitiveness Clusters'. It will benefit from EUR 13.4 million of public funding after the final signing with OSEO.

These subsidies and reimbursable advances will be allocated between the project's French institutions and financed partner SMEs.

IMODI's forecasted overall investment budget of EUR 41 million also includes private investment. Over the next ten years the project will create 350 jobs within the partner companies.

With EUR 300 million in funding available to OSEO, the call for 'Focal-Point Projects for Competitiveness Clusters in Research and Development' aims to support ambitious research and development partnership projects focusing on a particular industry or area of technology which offers significant potential for economic spin-offs.

"This project offers a unique opportunity to increase the rate of innovation and identification of cancer therapies and biomarkers, with the creation of an organized national structure designed for the development of personalized medicine which directly benefits patients," says Philippe Genne, Oncodesign's president and CEO.

"OSEO is proud to have provided support to the IMODI project on behalf of the French state, as part of the Investing for the Future program," adds Francois Drouin, CEO at OSEO and vice-president at the French Public Investment Bank.

Drouin continued, "The industry's requirements, the way that the partner organizations complement each other as well as their experience and collective interest, demonstrate the synergy which will ensure the sustainability of the sector and the creation of economic and scientific value in France."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.
Tuesday, September 10, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!